Lasa Supergenerics Ltd.

View in App
29.00 +0.33 ▲1.2%

08 December 2023, 04:01:00 PM
Volume: 16,274

Company Profile

View details >>
Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.lasalabs.com
Market Cap 144.34 Cr.
Enterprise Value(EV) 144.58 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) -4.97 Trailing Twelve Months Ending 2023-09
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2023-09
Industry PE 38.54 Trailing Twelve Months Ending 2023-09
Book Value / Share 22.62 Trailing Twelve Months Ending 2023-09
Price to Book Value 1.27 Calculated using Price: 28.81
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 5.01 Cr. 50,101,239 Shares
FaceValue 10
About Lasa Supergenerics Ltd.
The company is specialises in ‘catalyst chemistry' and manufactures anthelmintic/ veterinary API products with the largest production capabilities and product categories in India

Lasa Supergenerics Ltd. Delivery

View details >>
Delivered Qty
Traded Qty

Lasa Supergenerics Ltd. Performance

View details >>
1 Day
+1.15%
1 Week
+7.25%
1 Month
+11.93%
3 Month
-2.13%
6 Month
+21.44%
1 Year
-18.31%
2 Year
-55.83%
5 Year
+37.12%
10 Year

Lasa Supergenerics Ltd. Fundamental Ratios

View details >>
8 years 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 8.65 14.33 -10.81 2.94 15.17 -3.37 -27.97
Return on Capital Employed (%) 14.45 12.80 -3.73 6.77 17.14 -3.41 -23.94
Return on Assets (%) 2.07 4.79 -4.44 1.50 10.43 -2.56 -20.71

Lasa Supergenerics Ltd. Balance Sheet

View details >>
Particulars 9 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 0 75 117 105 141 159 158 118 113
Non Curr. Liab. 0 83 62 43 11 8 7 3 7
Curr. Liab. 70 107 107 76 41 45 43 46
Minority Int.
Equity & Liab. 0 228 287 255 229 208 209 164 166
Non Curr. Assets 149 178 170 153 144 143 125 120
Curr. Assets 0 79 109 86 76 64 66 39 45
Misc. Exp. not W/O 0
Total Assets 0 228 287 255 229 208 209 164 166

Lasa Supergenerics Ltd. Profit and Loss

View details >>
Particulars 9 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09 Rs. Cr. TTM
Net Sales 199 244 170 167 202 137 130 122
Other Income 2 3 1 0 0 0 2 2
Total Income 201 247 170 167 203 137 131 124
Total Expenditure -153 -202 -159 -137 -155 -121 -136 -115
PBIDT 48 45 12 30 47 16 -5 9
Interest -12 -11 -8 -8 -2 0 -4 -2
Depreciation -8 -18 -19 -17 -16 -15 -13 -13
Taxation 0 -3 4 -1 -7 1 4 1
Exceptional Items -26 -8 -20 -20
PAT 2 12 -12 4 23 -5 -39 -25
Adjusted EPS 472 5 -5 1 6 -1 -8 -5

Lasa Supergenerics Ltd. Cash Flow

View details >>
Particulars 8 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 0 -3 40 41 14 41 9 -17
Cash Fr. Inv. 0 -44 -7 -2 -4 -3 11
Cash Fr. Finan. 0 0 4 -33 -10 -36 0 -4
Net Change 0 -3 0 0 2 1 6 -10
Cash & Cash Eqvt 0 0 1 0 3 4 11 1

Lasa Supergenerics Ltd. Shareholding Pattern

View details >>
9 Qtrs 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%)
Promoter 64.47 45.01 43.78 43.78 43.78 43.78 53.65 53.65 53.65
Public 35.53 54.99 56.22 56.22 56.22 56.22 46.35 46.35 46.35
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 43.23 35.15 31.19 31.19 31.19 20.66 20.66 20.66

Lasa Supergenerics Ltd. Announcements

View details >>
Fri, 10 Nov 2023
Board Meeting Outcome for Outcome Of Board Meeting
Pursuant to Regulation 29 and 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulation 2015 we would like to inform you that the Board of Director in their Meeting Held Today which was Commenced at 3.00 PM and Concluded at 05.15 P.M.
Fri, 10 Nov 2023
Disclosure Of Related Party Transaction Under Regulation 23(9) Of SEBI (Listing Obligation And Disclosure Requirement) Regulation 2015
Pursuant to Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirement )Regulation 2015
Sat, 04 Nov 2023
Board Meeting Intimation for Unaudited Financial Results Of The Company For Q2
Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation 2015 notice is hereby given that Meeting of the Board of Director of the Company is scheduled to be held on Friday November 10 2023

Lasa Supergenerics Ltd. Technical Scans

View details >>
Fri, 08 Dec 2023
High Delivery Percentage High Delivery Percentage
Making Higher Highs for 3 days Making Higher Highs for 3 days
Close Above Last Week High Close Above Last Week High
Close Above Last Month High Close Above Last Month High
Making Higher Highs for 2 Days Making Higher Highs for 2 Days

Lasa Supergenerics Ltd. Related Stocks

View details >>
  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 296,437.84 1,235.50 -0.3%
Cipla Ltd. 98,403.90 1,218.85 -0.3%
Divi's Laboratories Ltd. 97,728.28 3,681.35 -1.4%
Dr. Reddy's Laboratories Ltd. 96,135.30 5,763.50 -0.4%
Apollo Hospitals Enterprise Ltd. 79,685.46 5,542.00 +1.5%
Mankind Pharma Ltd. 78,250.95 1,953.40 -2.2%
Torrent Pharmaceuticals Ltd. 69,584.38 2,056.00 -2.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-09 34.68 1,235.50 -0.3%
Cipla Ltd. Consolidated 2023-09 28.50 1,218.85 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-09 73.38 3,681.35 -1.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-09 18.88 5,763.50 -0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-09 114.25 5,542.00 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 61.04 1,953.40 -2.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-09 52.16 2,056.00 -2.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-09 4.96 1,235.50 -0.3%
Cipla Ltd. Consolidated 2023-09 3.96 1,218.85 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-09 7.71 3,681.35 -1.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-09 3.77 5,763.50 -0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-09 12.26 5,542.00 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 9.28 1,953.40 -2.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-09 10.37 2,056.00 -2.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,235.50 -0.3%
Cipla Ltd. Consolidated 2023-03 0.02 1,218.85 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,681.35 -1.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 5,763.50 -0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 5,542.00 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 1,953.40 -2.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,056.00 -2.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,235.50 -0.3%
Cipla Ltd. Consolidated 2023-03 12.85 1,218.85 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,681.35 -1.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,763.50 -0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 5,542.00 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 1,953.40 -2.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,056.00 -2.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,235.50 -0.3%
Cipla Ltd. Consolidated 2023-03 12.85 1,218.85 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,681.35 -1.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,763.50 -0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 5,542.00 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 1,953.40 -2.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,056.00 -2.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,235.50 -0.3%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,218.85 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,681.35 -1.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 5,763.50 -0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 5,542.00 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 1,953.40 -2.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,056.00 -2.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,235.50 -0.3%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,218.85 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,681.35 -1.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 5,763.50 -0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 5,542.00 +1.5%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 1,953.40 -2.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,056.00 -2.2%

Lasa Supergenerics Ltd. FAQ's

What is Lasa Supergenerics share price?
Can I buy Lasa Supergenerics shares now?
What is the Market Cap of Lasa Supergenerics?
What are the key metrics to analyse Lasa Supergenerics?
What is the 52 Week High and Low of Lasa Supergenerics?
What is the trend of Lasa Supergenerics share price?